Laskin J - Search Results

1

An advance in small-cell lung cancer treatment--more or less.

Laskin J, Sandler A, Johnson DH. Laskin J, et al. J Natl Cancer Inst. 2003 Aug 6;95(15):1099-101. doi: 10.1093/jnci/djg013. J Natl Cancer Inst. 2003. PMID: 12902431 Review. No abstract available.

2

The importance of the eicosanoid pathway in lung cancer.

Laskin JJ, Sandler AB. Laskin JJ, et al. Lung Cancer. 2003 Aug;41 Suppl 1:S73-9. doi: 10.1016/s0169-5002(03)00145-4. Lung Cancer. 2003. PMID: 12867065 Review.

3

Epidermal growth factor receptor: a promising target in solid tumours.

Laskin JJ, Sandler AB. Laskin JJ, et al. Cancer Treat Rev. 2004 Feb;30(1):1-17. doi: 10.1016/j.ctrv.2003.10.002. Cancer Treat Rev. 2004. PMID: 14766123 Review.

4

Redefining bronchioloalveolar carcinoma.

Laskin JJ, Sandler AB, Johnson DH. Laskin JJ, et al. Semin Oncol. 2005 Jun;32(3):329-35. doi: 10.1053/j.seminoncol.2005.02.013. Semin Oncol. 2005. PMID: 15988687 Review.

5

Epidermal growth factor receptor inhibitors in lung cancer therapy.

Laskin JJ, Sandler AB. Laskin JJ, et al. Semin Respir Crit Care Med. 2004;25 Suppl 1:17-27. doi: 10.1055/s-2004-829641. Semin Respir Crit Care Med. 2004. PMID: 16088517

6

State of the art in therapy for non-small cell lung cancer.

Laskin JJ, Sandler AB. Laskin JJ, et al. Cancer Invest. 2005;23(5):427-42. doi: 10.1081/cnv-67172. Cancer Invest. 2005. PMID: 16193643 Review.

7

The role of prophylactic cranial radiation in the treatment of non-small-cell lung cancer.

Laskin JJ, Sandler AB. Laskin JJ, et al. Clin Adv Hematol Oncol. 2003 Dec;1(12):731-34. Clin Adv Hematol Oncol. 2003. PMID: 16258477 Review.

8

First-line treatment for advanced non-small-cell lung cancer.

Laskin JJ, Sandler AB. Laskin JJ, et al. Oncology (Williston Park). 2005 Nov;19(13):1671-6; discussion 1678-80. Oncology (Williston Park). 2005. PMID: 16425521 Review.

9

A phase II study of carboplatin and irinotecan in extensive stage small-cell lung cancer.

Horn L, Zhao Z, Sandler A, Johnson D, Shyr Y, Wolff S, Devore RF, Laskin J. Horn L, et al. Among authors: laskin j. Clin Lung Cancer. 2011 May;12(3):161-5. doi: 10.1016/j.cllc.2011.03.013. Epub 2011 Apr 27. Clin Lung Cancer. 2011. PMID: 21663858 Clinical Trial.

10

Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.

Papadimitrakopoulou VA, Han JY, Ahn MJ, Ramalingam SS, Delmonte A, Hsia TC, Laskin J, Kim SW, He Y, Tsai CM, Hida T, Maemondo M, Kato T, Jenkins S, Patel S, Huang X, Laus G, Markovets A, Thress KS, Wu YL, Mok T. Papadimitrakopoulou VA, et al. Among authors: laskin j. Cancer. 2020 Jan 15;126(2):373-380. doi: 10.1002/cncr.32503. Epub 2019 Nov 26. Cancer. 2020. PMID: 31769875 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

783 results

Search Page

Filters